Published in Drug Week, November 19th, 2010
"The objective of this study was to estimate the economic impact of class I BCS-based biowaivers, along with the economic impact of a potential...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.